Morana Vojnic, Director of Neuro-Oncology, Rutgers Cancer Institute, System Leader for Neuro-Oncology, Robert Wood Johnson Barnabas Health, shared on LinkedIn:
“Excited to share that our neuro-oncology research student Rajika Chauhan, BS (Rutgers New Jersey Medical School/Rutgers Cancer Institute) presented our research poster at the ASCO/SNO CNS Metastases Conference 2026!
Title: Population-level survival improvement in HR+/HER2+ de novo breast cancer with brain metastases in the ADC era: a SEER analysis.
Key Takeaways:
- Survival Gain: In HR+/HER2+ de novo breast cancer brain metastases, median overall survival improved from 20 months pre-ADC (2010–2019) to not yet reached in the ADC era (2020–2023, p=0.005).
- Mortality Reduction: 36-month cause-specific survival rose from 36.8% to 52.7% (HR=0.833, p=0.0009).
- Impact: Demonstrates that recent trial advances with HER2-directed ADCs are translating into real-world survival improvements.
Congrats to Rajika Chauhan and co-authors Jonathan Sherman, Coral Omene!
You can also read:
Lizza Hendriks: Breaking Barriers, Redefining Brain Metastases Treatment Concepts
